Use of Platelet Rich Plasma (PRP) in the Treatment of Acute Post Intubation Tracheal Rupture: Report of Two Cases

Abstract

The use of PRP involves a complex network of molecular events which accelerate tissue regeneration due to its richness in growth factors plus a variety of biologic mediators. Several communications tell us about its usefulness on the dental implantology field, plastic surgery, orthopedics and peripheral nerve regeneration after trauma. We have presented our successful experience of its use in pneumology when treating severe hemoptysis, respiratory fistulae, spontaneous pneumothorax and one tracheal rupture. In this article we present two cases of post intubation tracheal rupture successfully treated with the local instillation of PRP on one of them and with the injection of PRP along the lips of the tracheal wound on the other. Tracheal rupture is a rare but life threatening complication of emergency intubation requiring an effective response in order to avoid the risk of patient death due to secondary mediastinitis and sepsis. Up to now there is no general consensus in the treatment of this condition and alternatives in use are not universally accepted. The use of local autologous PRP in our experience has demonstrated a favorable performance in such cases, turning it in a highly promising tool for the treatment of conditions such as this, in which a rapidly effective and minimally invasive handling is required.

Plasma rico en plaquetas como terapia autóloga en la medicina regenerativa: Revisión narrativa

“…El resultado favorable en las situaciones clínicas planteadas indica que puede ser un tratamiento definitivo (Shareef et al, 2020), ya que regenera la función respiratoria, acorta el tiempo de estadía hospitalaria y abre la posibilidad de usarlo en casos de neumología, como enfisema pulmonar de los lóbulos superiores. En un estudio reciente, los autores utilizan PRP autólogo local con resultados rápidos y efectivos en dos casos de ruptura traqueal aguda post intubación (Rioseco et al, 2020).…”